BioCentury | Aug 9, 2019
Emerging Company Profile

Owkin: machine learning with privacy protection

To better protect patient privacy in its machine learning-based analyses of real-world data for optimization of drug development and trial design, Owkin’s technology leaves patient data in the originating institutions. Gilles Wainrib, Owkin’s co-founder and...
BC Extra | Jul 9, 2019
Financial News

July 9 Financial Quick Takes: ADC tops off megaround with $27M; plus Genmab, GNS, StemRIM and more

ADC closes expanded E round at $303M   ADC Therapeutics S.A. (Lausanne, Switzerland) raised an additional $27 million in its expanded series E round, which closed at $303 million. In June, the developer of antibody-drug...
BioCentury | Mar 23, 2019
Tools & Techniques

A frequentist and a Bayesian walk into a trial

In the stand-off between Bayesians and frequentists, the latter own the show for pivotal trials. But with non-profits leading the drive, Bayesians are poised to enter late-stage development via platform trials in cancer. The next...
BioCentury | Feb 23, 2019
Tools & Techniques

Modeling now for precision later

GNS Healthcare Inc. is building a platform that aims to make value-based payment models unnecessary by giving companies a way to know which patients will respond before they even launch the drug. While drug companies...
BC Week In Review | Nov 30, 2018
Company News

Merck KGaA, Palantir team up to drive cancer research data collaboration

Merck KGaA (Xetra:MRK) and big data company Palantir Technologies (Palo Alto, Calif.) plan to create a JV under the name Syntropy to help facilitate collaboration among cancer researchers. Syntropy will offer a data integration software...
BC Extra | Nov 20, 2018
Company News

Merck KGaA, Palantir team up to drive cancer research data sharing and integration

Merck KGaA (Xetra:MRK) and big data company Palantir Technologies (Palo Alto, Calif.) plan to create a JV under the name Syntropy to help facilitate collaboration among cancer researchers. Syntropy will offer a data integration software...
BC Extra | Oct 4, 2018
Company News

Management tracks: Grail, Nimbus

Cancer detection company Grail Inc. (Menlo Park, Calif.) hired Renée Galá as its first CFO, effective Jan. 3. Gala is SVP and CFO at Theravance Biopharma Inc. (NASDAQ:TBPH). Grail launched in 2016 and has raised...
BC Week In Review | Sep 14, 2018
Company News

GNS, Amgen to use AI to explore patient response to mCRC drug Vectibix

GNS Healthcare Inc. (Cambridge, Mass), Amgen Inc. (NASDAQ:AMGN) and the Alliance for Clinical Trials in Oncology (Boston, Mass.) partnered to use artificial intelligence to identify factors that drive and predict patient responses to Amgen’s metastatic...
BioCentury | Sep 1, 2018
Politics, Policy & Law

Back to School: A pathway to Biopharma 3.0

As market and social forces continue to tighten around the biopharmaceutical industry, drug companies need to start evolving toward a new business model that both capitalizes on the potential of new technologies and accommodates society’s...
BC Extra | Aug 23, 2018
Company News

Management tracks: E-Scape, Immunomedics

Neurodegeneration company E-Scape Bio Inc. (South San Francisco, Calif.) hired Julie Smith as president and CEO. Smith was president and CEO at Nuredis Inc. (Menlo Park, Calif.). Smith succeeds former CEO Leon Chen, who is...
Items per page:
1 - 10 of 60
BioCentury | Aug 9, 2019
Emerging Company Profile

Owkin: machine learning with privacy protection

To better protect patient privacy in its machine learning-based analyses of real-world data for optimization of drug development and trial design, Owkin’s technology leaves patient data in the originating institutions. Gilles Wainrib, Owkin’s co-founder and...
BC Extra | Jul 9, 2019
Financial News

July 9 Financial Quick Takes: ADC tops off megaround with $27M; plus Genmab, GNS, StemRIM and more

ADC closes expanded E round at $303M   ADC Therapeutics S.A. (Lausanne, Switzerland) raised an additional $27 million in its expanded series E round, which closed at $303 million. In June, the developer of antibody-drug...
BioCentury | Mar 23, 2019
Tools & Techniques

A frequentist and a Bayesian walk into a trial

In the stand-off between Bayesians and frequentists, the latter own the show for pivotal trials. But with non-profits leading the drive, Bayesians are poised to enter late-stage development via platform trials in cancer. The next...
BioCentury | Feb 23, 2019
Tools & Techniques

Modeling now for precision later

GNS Healthcare Inc. is building a platform that aims to make value-based payment models unnecessary by giving companies a way to know which patients will respond before they even launch the drug. While drug companies...
BC Week In Review | Nov 30, 2018
Company News

Merck KGaA, Palantir team up to drive cancer research data collaboration

Merck KGaA (Xetra:MRK) and big data company Palantir Technologies (Palo Alto, Calif.) plan to create a JV under the name Syntropy to help facilitate collaboration among cancer researchers. Syntropy will offer a data integration software...
BC Extra | Nov 20, 2018
Company News

Merck KGaA, Palantir team up to drive cancer research data sharing and integration

Merck KGaA (Xetra:MRK) and big data company Palantir Technologies (Palo Alto, Calif.) plan to create a JV under the name Syntropy to help facilitate collaboration among cancer researchers. Syntropy will offer a data integration software...
BC Extra | Oct 4, 2018
Company News

Management tracks: Grail, Nimbus

Cancer detection company Grail Inc. (Menlo Park, Calif.) hired Renée Galá as its first CFO, effective Jan. 3. Gala is SVP and CFO at Theravance Biopharma Inc. (NASDAQ:TBPH). Grail launched in 2016 and has raised...
BC Week In Review | Sep 14, 2018
Company News

GNS, Amgen to use AI to explore patient response to mCRC drug Vectibix

GNS Healthcare Inc. (Cambridge, Mass), Amgen Inc. (NASDAQ:AMGN) and the Alliance for Clinical Trials in Oncology (Boston, Mass.) partnered to use artificial intelligence to identify factors that drive and predict patient responses to Amgen’s metastatic...
BioCentury | Sep 1, 2018
Politics, Policy & Law

Back to School: A pathway to Biopharma 3.0

As market and social forces continue to tighten around the biopharmaceutical industry, drug companies need to start evolving toward a new business model that both capitalizes on the potential of new technologies and accommodates society’s...
BC Extra | Aug 23, 2018
Company News

Management tracks: E-Scape, Immunomedics

Neurodegeneration company E-Scape Bio Inc. (South San Francisco, Calif.) hired Julie Smith as president and CEO. Smith was president and CEO at Nuredis Inc. (Menlo Park, Calif.). Smith succeeds former CEO Leon Chen, who is...
Items per page:
1 - 10 of 60